Tuya Mungan, MongoliaNational Center of Communicable Diseases Virology
Author Of 2 Presentations
PNEUMOCOCCAL CONJUGATE VACCINE IS EFFECTIVENESS AGAINST HYPOXIC PNEUMONIA IN LAOS, MONGOLIA AND PAPUA NEW GUINEA: A NOVEL CASE-CONTROL VARIANT STUDY (ID 852)
- Fiona M. Russell, Australia
- Cattram D. Nguyen, Australia
- Rupert Weaver, Australia
- Christopher C. Blyth, Australia
- Jocelyn Chan,
- Claire Von Mollendorf, Australia
- Kate Britton, Australia
- David A. Dance, Laos
- Rebecca Ford, Papua New Guinea
- Jana Y. Lai, Australia
- Tuya Mungan, Mongolia
- Paul N. Newton, United Kingdom
- Kim E. Mulholland, Australia
- William Pomat, Papua New Guinea
- Keoudomphone Vilivong, Laos
- Anonh Xeuatvongsa, Laos
We describe a novel approach to determine PCV13 effectiveness (VE) against hypoxic pneumonia in children admitted with pneumonia in Lao PDR (Laos), Mongolia and Papua New Guinea (PNG).
A 3-5 year prospective hospital-based observational study of children <59 months admitted with pneumonia was undertaken. Pneumonia was defined using the 2013 WHO definition. Hypoxia was defined as an oxygen saturation <90% in room air or requiring oxygen supplementation during hospitalisation. PCV13 status was determined by written record. VE was calculated using logistic regression comparing the odds of hypoxia between vaccinated and undervaccinated pneumonia cases. To handle potential confounders a propensity score (PS) analysis using inverse probability of treatment weighting (IPW) was used. In Laos, multiple imputation (MI) analysis was undertaken for missing data.
The VE against hypoxic pneumonia were: in Laos, unadjusted 23% (95% CI: -9, 46%; p=0·14), PS adjusted IPW 37% (6, 57%; p=0·02), MI adjusted 35% (7, 55%; p=0·02); in Mongolia, unadjusted 33% (26, 40%; p<0.001), PS adjusted IPW 33% (16, 47%; p<0.001); and in PNG, unadjusted 6% (-15, 24%; p=0.532), PS adjusted IPW 36% (17, 51%; p=0.001).
Our novel approach shows that PCV13 is effective against hypoxic pneumonia. PCV13 will contribute to reducing child mortality.